The Path Forward for Covid-19 Therapeutics

This editorial summarizes an audio interview with NEJM editors discussing prospects for emerging Covid-19 treatments. The conversation, recorded on February 21, 2023, highlights interferon lambda as a potential therapeutic agent, considering its mechanism, clinical promise, and deployment challenges. Editors emphasize the continued global transmission of SARS-CoV-2 and the necessity of informed guidance from infectious disease experts. The interview underscores the evolving landscape of Covid-19 pharmacologic responses and the critical need for evidence-based decision-making.

This editorial summarizes an audio interview with NEJM editors discussing prospects for emerging Covid-19 treatments. The conversation, recorded on February 21, 2023, highlights interferon lambda as a potential therapeutic agent, considering its mechanism, clinical promise, and deployment challenges. Editors emphasize the continued global transmission of SARS-CoV-2 and the necessity of informed guidance from infectious disease experts. The interview underscores the evolving landscape of Covid-19 pharmacologic responses and the critical need for evidence-based decision-making.